Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885721 | 0.96 | NR1H4 (0.74) | NR1H4POLBCNR1HPGDBACE1 | |
| Vonafexor SCHEMBL1893285 | 0.91 | NR1H4 (0.81) | NR1H4POLBCNR1HPGDATM | |
| SCHEMBL1891845 | 0.89 | NR1H4 (0.64) | NR1H4HPGDBACE1KMT2AGLA | |
| SCHEMBL29880902 | 0.89 | NR1H4 (0.64) | NR1H4HPGDBACE1KMT2AGLA | |
| SCHEMBL29880947 | 0.89 | NR1H4 (0.63) | NR1H4HPGDBACE1KMT2AGLA | |
| SCHEMBL29881011 | 0.89 | NR1H4 (1.00) | NR1H4POLBCNR1HPGDKMT2A | |
| SCHEMBL1883857 | 0.89 | NR1H4 (0.63) | NR1H4HPGDBACE1KMT2AGLA | |
| SCHEMBL1888135 | 0.89 | NR1H4 (1.00) | NR1H4POLBCNR1HPGDKMT2A | |
| SCHEMBL30725404 | 0.88 | NR1H4 (0.77) | NR1H4POLBCNR1HPGDATM | |
| SCHEMBL29174572 | 0.88 | NR1H4 (0.77) | NR1H4POLBCNR1HPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4277630-A1 | METHOD FOR TREATING CHRONIC KIDNEY DISEASES | ENYO Pharma (FR) | 2023-11-22 | — | — | EP | claimed |
| CN-116685321-A | Methods for treating chronic kidney disease | 埃尼奥制药公司 | 2023-09-01 | — | — | CN | claimed |
| US-20230165853-A1 | METHOD FOR TREATING CHRONIC KIDNEY DISEASES | ENYO PHARMA (FR) | 2023-06-01 | — | — | US | claimed |
| WO-2022152773-A1 | METHOD FOR TREATING CHRONIC KIDNEY DISEASES | ENYO PHARMA (FR) | 2022-07-21 | — | — | WO | claimed |
| EP-2262785-B1 | BENZOFURANE DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH (DE) | 2015-01-14 | — | — | EP | claimed |
| US-8575161-B2 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | claimed |
| US-20110105475-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERXCK PATENT GESELLSCHAFT (DE) | 2011-05-05 | — | — | US | claimed |
| EP-2262785-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | Merck Patent GmbH (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009127321-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH, (DE) | 2009-10-22 | — | — | WO | claimed |
| EP-2110374-A1 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | Merck Sante (FR) | 2009-10-21 | — | — | EP | claimed |
| EP-4277630-A1 | METHOD FOR TREATING CHRONIC KIDNEY DISEASES | ENYO Pharma (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116685321-A | Methods for treating chronic kidney disease | 埃尼奥制药公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230165853-A1 | METHOD FOR TREATING CHRONIC KIDNEY DISEASES | ENYO PHARMA (FR) | 2023-06-01 | — | — | US | disclosed |
| US-20230165853-A1 | METHOD FOR TREATING CHRONIC KIDNEY DISEASES | ENYO PHARMA (FR) | 2023-06-01 | — | — | US | disclosed |
| US-20230165853-A1 | METHOD FOR TREATING CHRONIC KIDNEY DISEASES | ENYO PHARMA (FR) | 2023-06-01 | — | — | US | disclosed |
| US-8575161-B2 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20110105475-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERXCK PATENT GESELLSCHAFT (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2262785-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | Merck Patent GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009127321-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH, (DE) | 2009-10-22 | — | — | WO | disclosed |
| EP-2110374-A1 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | Merck Sante (FR) | 2009-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165853-A1 | METHOD FOR TREATING CHRONIC KIDNEY DISEASES | REN, ATP6V1B1, GLS | NR1H4 145/4885POLB 3955/4885CNR1 582/4885 |
| US-20110105475-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | FXR1, FXR2, NR1H4 | NR1H4 3/4885POLB 3866/4885CNR1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.